Table 2.
Information of clinical characteristics and laboratory data in the NCAD group and the CAD group.
| Characteristics | NCAD (n = 36) | CAD (n = 123) | P |
|---|---|---|---|
| Gender (M/F) | 20/16 | 78/45 | 0.438 |
| Age (years) | 63 (51, 74) | 64 (57, 73) | 0.465 |
| Smoking (n, %) | 6 (16.7%) | 38 (30.9%) | 0.137 |
| Drinking (n, %) | 2 (5.56%) | 22 (17.9%) | 0.110 |
| Hypertension (n, %) | 25 (69.4%) | 95 (77.2%) | 0.380 |
| Hyperlipidemia (n, %) | 14 (38.9%) | 39 (31.7%) | 0.428 |
| Diabetes (n, %) | 7 (19.4%) | 39 (31.7%) | 0.210 |
| Glu (mmol/L) | 5.33 (4.84, 5.68) | 5.53 (4.93, 6.45) | 0.119 |
| SBP (mmHg) | 147 (139, 155) | 144 (127, 158) | 0.627 |
| DBP (mmHg) | 80 (74, 93) | 82 (74, 90) | 0.818 |
| HDL-C (mmol/L) | 1.06 (0.87, 1.28) | 1.00 (0.83, 1.22) | 0.548 |
| LDL-C (mmol/L) | 2.20 (1.89, 2.54) | 2.03 (1.50, 2.58) | 0.174 |
| TC (mmol/L) | 4.16 (3.65, 5.04) | 4.10 (3.34, 4.83) | 0.338 |
| TG (mmol/L) | 1.38 (1.18, 1.82) | 1.45 (0.97, 2.23) | 0.951 |
| CRP (mg/L) | 0.94 (0.43, 2.06) | 4.04 (1.78, 10.4) | <0.001 |
| ADAMTS-5 (ng/mL) | 7.62 (5.60, 10.5) | 4.64 (3.02, 6.41) | <0.001 |
| MMP-2 (ng/mL) | 7.95 (5.06, 12.4) | 13.3 (9.09, 17.6) | <0.001 |
| MMP-9 (ng/mL) | 50.1 (34.8, 78.9) | 83.4 (59.0, 103.4) | <0.001 |
| Gensini score | — | 24 (10, 46) | — |
| Medications, n (%) | |||
| Aspirin | 13 (36.1%) | 62 (50.4%) | 0.184 |
| Statin | 8 (22.2%) | 47 (38.2%) | 0.110 |
| ACEI/ARB | 17 (47.2%) | 66 (53.6%) | 0.571 |
| CCB | 11 (30.5%) | 52 (42.3%) | 0.247 |
| β-Receptor blockers | 6 (16.7%) | 35 (28.5%) | 0.196 |
| Diuretic | 3 (8.33%) | 7 (5.69%) | 0.696 |
| Insulin | 4 (11.1%) | 22 (17.8%) | 0.446 |
| Oral hypoglycemics | 2 (5.56%) | 17 (13.8%) | 0.248 |
Data are expressed as median (interquartile range) or the number (percentage) for category variables. Glu: fasting glucose; SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; TC: total cholesterol; TG: total triglycerides; CRP: C-reactive protein; ADAMTS-5: a disintegrin and metalloproteinase with thrombospondin type 1 motif-5; MMP-2: matrix metalloproteinase-2; MMP-9: matrix metalloproteinase-9; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; CCB: calcium channel blockers.